

Tania Crombet Ramos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3616940/publications.pdf>

Version: 2024-02-01

75
papers

2,721
citations

218381

26
h-index

189595

50
g-index

80
all docs

80
docs citations

80
times ranked

2319
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 1646-1654.	0.8	261
2	Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. <i>MAbs</i> , 2009, 1, 41-48.	2.6	195
3	Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1452-1458.	0.8	189
4	Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. <i>Cancer Biology and Therapy</i> , 2010, 9, 343-349.	1.5	142
5	Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. <i>Cancer Biology and Therapy</i> , 2006, 5, 375-379.	1.5	137
6	Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile. <i>Cancer Biology and Therapy</i> , 2011, 11, 373-382.	1.5	127
7	A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 3782-3790.	3.2	116
8	A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 3660-3671.	3.2	109
9	Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti-Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non-Small-Cell Lung Cancer Patients Treated with the Epidermal Growth Factor Cancer Vaccine. <i>Clinical Cancer Research</i> , 2008, 14, 840-846.	3.2	106
10	Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer. <i>Journal of Immunotherapy</i> , 2003, 26, 139-148.	1.2	102
11	Therapeutic Vaccination with Epidermal Growth Factor (EGF) in Advanced Lung Cancer: Analysis of Pooled Data from Three Clinical Trials. <i>Hum Vaccin</i> , 2007, 3, 8-13.	2.4	65
12	Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. <i>BMC Cancer</i> , 2013, 13, 299.	1.1	61
13	Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy. <i>Cancer Biology and Therapy</i> , 2012, 13, 600-605.	1.5	60
14	CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2017, 8, 269.	2.2	56
15	Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung Cancer. <i>Journal of Immunotherapy</i> , 2009, 32, 92-99.	1.2	54
16	Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study. <i>Clinical Cancer Research</i> , 2010, 16, 2474-2482.	3.2	54
17	Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 37-45.	2.0	53
18	Treatment of NSCLC patients with an EGF-based cancer vaccine: Report of a phase I trial. <i>Cancer Biology and Therapy</i> , 2006, 5, 145-149.	1.5	51

#	ARTICLE	IF	CITATIONS
19	A view on EGFR-targeted therapies from the oncogene-addiction perspective. <i>Frontiers in Pharmacology</i> , 2013, 4, 53.	1.6	41
20	Nimotuzumab: beyond the EGFR signaling cascade inhibition. <i>Seminars in Oncology</i> , 2018, 45, 18-26.	0.8	40
21	Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.. <i>Hum Vaccin</i> , 2010, 6, 736-744.	2.4	36
22	Nimotuzumab in combination with radiotherapy in high grade glioma patients. <i>Cancer Biology and Therapy</i> , 2014, 15, 504-509.	1.5	36
23	Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. <i>Frontiers in Pharmacology</i> , 2017, 8, 382.	1.6	36
24	Control of Advanced Cancer: The Road to Chronicity. <i>International Journal of Environmental Research and Public Health</i> , 2011, 8, 683-697.	1.2	33
25	Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. <i>Journal of Immune Based Therapies and Vaccines</i> , 2011, 9, 7.	2.4	29
26	EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. <i>Cancers</i> , 2011, 3, 2014-2031.	1.7	29
27	Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with ^{99m} Tc in patients with tumour of epithelial origin. <i>Nuclear Medicine Communications</i> , 2005, 26, 1049-1057.	0.5	28
28	CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer. <i>Expert Review of Vaccines</i> , 2015, 14, 1303-1311.	2.0	28
29	A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. <i>Cancer Biology and Therapy</i> , 2015, 16, 684-689.	1.5	26
30	Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience. <i>MAbs</i> , 2013, 5, 202-207.	2.6	25
31	Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody against Epidermal Growth Factor Receptor. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2001, 16, 93-102.	0.7	24
32	Systemic and skin toxicity in cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab. <i>Cancer Biology and Therapy</i> , 2007, 6, 1386-1391.	1.5	24
33	Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck. <i>Frontiers in Oncology</i> , 2020, 10, 817.	1.3	24
34	Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. <i>Annals of Medicine</i> , 2003, 35, 327-36.	1.5	24
35	Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. <i>Hum Vaccin</i> , 2010, 6, .	2.4	23
36	Immunosenescence and gender: a study in healthy Cubans. <i>Immunity and Ageing</i> , 2013, 10, 16.	1.8	20

#	ARTICLE	IF	CITATIONS
37	Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19. <i>Gerontology</i> , 2020, 66, 553-561.	1.4	20
38	CIMAvax-EGF: Toward long-term survival of advanced NSCLC. <i>Seminars in Oncology</i> , 2018, 45, 34-40.	0.8	19
39	An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. <i>Immunity and Ageing</i> , 2020, 17, 34.	1.8	18
40	Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial. <i>Frontiers in Pharmacology</i> , 2017, 8, 263.	1.6	17
41	Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment. <i>Immunotherapy</i> , 2022, 14, 521-530.	1.0	17
42	Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 261-270.	1.9	14
43	Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab. <i>Clinical and Translational Immunology</i> , 2020, 9, e1218.	1.7	13
44	Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly. <i>Experimental Gerontology</i> , 2019, 124, 110633.	1.2	11
45	Is there a subgroup of long-term evolution among patients with advanced lung cancer?: Hints from the analysis of survival curves from cancer registry data. <i>BMC Cancer</i> , 2014, 14, 933.	1.1	10
46	Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1735-1743.	2.0	10
47	Prolonged Use of Nimotuzumab in Children with Central Nervous System Tumors: Safety and Feasibility. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 173-178.	0.7	9
48	Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 737-747.	2.0	9
49	Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer. <i>Seminars in Oncology</i> , 2018, 45, 52-57.	0.8	9
50	Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule. <i>Oncolimmunology</i> , 2020, 9, 1762465.	2.1	9
51	An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases. <i>Immunotherapy</i> , 2021, 13, 289-295.	1.0	9
52	The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 639745.	1.3	9
53	Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy. <i>Journal of Immunotherapy</i> , 2017, 40, 289-301.	1.2	8
54	Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients. <i>BMC Cancer</i> , 2020, 20, 772.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Nimotuzumab for COVID-19: case series. <i>Immunotherapy</i> , 2022, 14, 185-193.	1.0	6
56	Immunoscintigraphy With ^{99m} Tc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, 244-246.	0.7	5
57	Pulmonary Thrombosis in COVID-19 Treated by Thrombolysis: A Small Case Series Using Streptokinase. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 431-435.	1.5	4
58	Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 823287.	1.3	4
59	Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 337-342.	1.0	3
60	COVID-19 and Cancer in Cuba. <i>Seminars in Oncology</i> , 2020, 47, 328-329.	0.8	3
61	Active immunotherapy in patients with progressive disease (PD) after first-line therapy: Racotumomab experience.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3086-3086.	0.8	3
62	EGF-based cancer vaccine: Optimizing predictive and surrogate biomarkers.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3013-3013.	0.8	3
63	P2.40: CIMAvaxEGF Vaccine for the Treatment of Real-World NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, S242.	0.5	2
64	Current Algorithm for Treatment of Advanced NSCLC Patients: How to Include Active Immunotherapy?. <i>Journal of Cancer Therapy</i> , 2013, 04, 59-75.	0.1	1
65	Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2515-2515.	0.8	1
66	EGF-based cancer vaccine for advanced NSCLC: Results from a phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2527-2527.	0.8	1
67	Del nuevo producto biol3gico para el c4ncer al impacto en la salud poblacional. <i>Revista Cubana De Salud Publica</i> , 2012, 38, 781-793.	0.0	0
68	Immunotherapy for Transforming Advanced Cancer into a Chronic Disease. , 2016, , 105-120.		0
69	Underlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer. <i>Quality of Life Research</i> , 2020, 29, 3441-3448.	1.5	0
70	Trial proactive: A prospective, randomized, multicenter, open label phase III study of active specific immunotherapy with racotumomab plus best support treatment versus best support treatment in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3123-TPS3123.	0.8	0
71	RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3111-TPS3111.	0.8	0
72	Evaluaci3n de CIMAvaxEGF para el tratamiento del c4ncer de pulm3n: meta-an4lisis de ensayos cl4nicos controlados. <i>Revista Bionatura</i> , 2017, 2, .	0.1	0

#	ARTICLE	IF	CITATIONS
73	Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients.. Journal of Clinical Oncology, 2017, 35, e15787-e15787.	0.8	0
74	Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials. Revista Bionatura, 2020, 5, 1056-1062.	0.1	0
75	Multicenter oncology clinical trials in primary health care in Cuba: evaluation of program implementation in Villa Clara Province, 2010-2020. BJGP Open, 2022, , BJGPO.2021.0165.	0.9	0